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ABSTRACT: High-throughput nucleotide sequencing
(often referred to as next-generation sequencing; NGS)
is increasingly being chosen as a diagnostic tool for cases
of expected but unresolved genetic origin. When explor-
ing a higher number of genetic variants, there is a higher
chance of detecting unsolicited findings. The consequen-
tial increased need for decisions on disclosure of these
unsolicited findings poses a challenge for the informed
consent procedure. This article discusses the ethical and
practical dilemmas encountered when contemplating in-
formed consent for NGS in diagnostics from a multidis-
ciplinary point of view. By exploring recent similar ex-
periences with unsolicited findings in other settings, an
attempt is made to describe what can be learned so far for
implementing NGS in standard genetic diagnostics. The
article concludes with a set of points to consider in order
to guide decision-making on the extent of return of results
in relation to the mode of informed consent. We hereby
aim to provide a sound basis for developing guidelines for
optimizing the informed consent procedure.
Hum Mutat 34:1322–1328, 2013. Published 2013 Wiley Period-
icals, Inc.∗
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Introduction
Advances in DNA sequencing techniques have intensified the use
of sequencing large parts of the genome (next-generation sequenc-
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ing, NGS) in research as well as in diagnostics. The challenge of NGS
in clinical practice is to identify the pathogenic variants among the
many thousands of (new) variants that could be detected in each
genome [Majewski et al., 2011]. When analyzing the sequence for
diagnostic purposes, the first step would preferably be a targeted
approach, searching for pathogenic variants in a panel of known
genes causing the clinical phenotype or in some cases for de novo
mutations by comparing a child’s genome with its parents [de Ligt
et al., 2012]. When this first step does not answer the clinical en-
quiry, more regions of the sequence can be examined, increasing
the chance of finding variants that lie outside of the clinical enquiry.
These variants may or may not have clinical implications for the
person himself and/or family members. In some cases, sequencing
may thus be seen as a kind of screening, where screening should
be understood as (predictive) testing without a specific indication
[Hastings et al., 2012; van El et al., 2013].
A term frequently used for findings not related to the primary
enquiry is “incidental finding” [Green et al., 2013]. However, since
in large-scale genomics applications we expect findings other than
the ones answering the clinical enquiry, these findings are not con-
sidered an incident. In this context, therefore, the term “unsolicited”
seems more appropriate, as is also proposed by the European Society
of Human Genetics [Hastings et al., 2012].
Before the advent of NGS, other existing diagnostic technologies
within and outside genetics (including imaging and karyotyping)
have existed with a low but significant chance of unsolicited findings
[Berland et al., 2010; Kohane et al., 2012]. With NGS, the prospects
for these findings are increased, requiring a re-examination of this
topic [Johnston et al., 2012; Netzer et al., 2009; Ostrer, 2011]. Con-
sequently, guidance is needed on what information should be dis-
cussed and consented to preceding the test; which results to disclose
to the patient (which may have consequences for relatives) and the
extent to which patients should decide on what should be reported
back to them [Berg et al., 2011; Ormond et al., 2010; Ostrer, 2011;
Thorogood et al., 2012]. Although the criteria for the informed
consent procedure for NGS are currently a subject of debate within
the professional community [Thorogood et al., 2012; Wright et al.,
2011], no practical guidance has been described so far [Jackson et al.,
2012].
To develop the best practice guidelines for an informed con-
sent procedure for NGS in diagnostics, an international and
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multidisciplinary expert meeting entitled “Exome sequencing in
diagnostics: exploring needs for the informed consent procedure”
was organized in Amsterdam, The Netherlands (March 2012, Supp.
Table S1). This article reflects the expert contributions and dis-
cussions of that meeting addressing specific questions, supported
by additional literature searches. It aims to describe what can be
learned so far and provides a set of questions that could be used
to provide a sound basis for developing an optimal informed con-
sent procedure for NGS in diagnostics. The following questions are
addressed: (1) What are the ethical challenges expected in the first ex-
periences with informed consent for NGS in diagnostics? (2) What
are the ethical and practical dilemmas encountered in discussions on
unsolicited findings and informed consent so far (from NGS and
similar settings)? (3) What are the practical needs and considerations
encountered in experiences with unsolicited findings and informed
consent?
Ethical Challenges Expected for Informed
Consent for NGS in Diagnostics: About Patient
Rights and Professional Duties
A patient’s right to informed consent requires a balance between
information overload and uninformed consent. As the range of
possible outcomes of diagnostic NGS is generally too wide to be
able to discuss and comprehend them all prior to testing, it has been
proposed that a “generic consent” would be appropriate [Dondorp
et al., 2012]. The extent to which “generic consent” is sufficiently
informed and how much information is needed requires further
study. These two aspects may well be context dependent.
When analyzing large parts of the genome diagnostically, a ques-
tion arises on the patient’s right to be informed about unsolicited
findings. Informing patients about all unsolicited findings might
not be practically possible due to time constraints; the cost of val-
idating all findings; and the outcomes being of very low relevance
such that informing patients might cause more harm than good (a
conflict between nonmaleficence [avoiding the causation of harm]
and autonomy).
In principle, patients also have a right not to be informed about
unsolicited findings. This would mean that when being asked to give
consent for a NGS-based test, patients should (within the limits of
practicality) be given the opportunity to indicate both: which un-
solicited findings they would want to be informed about and which
not. The latter might lead to difficult situations where the physician
is confronted with conflicting duties of respecting a patient’s right
not to know on the one hand and his/her duty to warn on the other.
Because patients (and physicians alike) might not be aware of
all possible implications of potential findings before specific re-
sults have been generated, it seems appropriate to inform the
patient about the fact that an absolute right not to know can-
not be guaranteed. Another reason for this is that the interests
of the patient’s relatives may also be at stake [Thorogood et al.,
2012]. In case of proxy consent (e.g., parents or legal representa-
tives giving consent for their child), parents cannot claim a right
not to know with regard to unsolicited findings that would be
directly relevant for the child’s health in the sense of requiring
treatment, prevention, or surveillance. Furthermore, the right to
know of parents is not absolute, since children also have a “right
to an open future” [Bredenoord et al., 2013; Dondorp et al.,
2012].
Experiences with Unsolicited Findings and
Informed Consent So Far
How to deal with unsolicited findings and the implications for
informed consent has been discussed in different medical settings,
for example, in the context of imaging [e.g., Mirilas and Skandalakis,
2002], neonatal screening [e.g., Miller et al., 2009], genetic research
[e.g., Wolf et al., 2008], array comparative genomic hybridization
(ArrayCGH) [e.g., Pichert et al., 2011], and NGS in diagnostics
[e.g., Ormond et al., 2010]. A selection of experiences in these
different settings is described here to explore the ethical and practical
dilemmas encountered.
Disclosing Carrier Status in Newborn Screening
Although newborn screening typically aims to identify newborns
with severe disorders to start early treatment, as a result of the
screening technology a heterozygous carrier status is (unsolicitedly)
found in a relatively large proportion of children, for example, with
regard to haemoglobinopathies. The detection of carriers and feed-
back of this information to parents has generated much discussion
[Bombard et al., 2009; Miller et al., 2009]. Carrier status has no
direct implications for the child being screened, but the informa-
tion could be relevant in adult life, for example, with regard to
reproductive choices. Because of additional potential relevance for
family members and future reproductive decision making for the
parents, it was decided in some countries that by default parents
should be informed about this result. However, since it is not a goal
of the screening, in some jurisdictions, parents can opt out for this
finding, for example, in The Netherlands, by signing the bloodspot
card (Supp. Fig. S1). It should be noted that the discussion about
how to handle this specific unsolicited finding is still ongoing and
that no (international) consensus exists [Bombard and Miller, 2012;
Bombard et al., 2012; Ross, 2012]. In this example, the result is
anticipated and it concerns only one type of outcome (heterozy-
gous carrier status of a specified recessive disorder), which makes
the informed consent procedure less complex than with NGS in
diagnostics.
Feedback of Actionable Results from Genetic Research
In research, it is common practice that extensive informed consent
is requested, whereas traditionally, there is no (or little) feedback of
results. Increasingly, actionable results are being fed back to research
participants, for example, in some population studies where new
genomic techniques are used, with implications for the informed
consent procedure [Knoppers et al., 2013]. An example comes from
a cancer genetics study in Helsinki. This study, which started in
2011, uses NGS techniques, but unsolicited findings occur very
rarely because of the targeted analysis. Research participants are
given the option to be informed of any relevant finding from this
study (Supp. Fig. S2).
Concerns are expressed about the practicalities inherent in feed-
ing back research results including the validation of abnormal results
and the implications for cascading clinically significant results when
reporting findings [Miller et al., 2012]. These cascading obligations
involve ensuring reliable and updated information and providing
access to appropriate care that are often outside the scope of the
research project, blurring the boundaries between research and clin-
ical care [Hastings et al., 2012], and requiring specialist clinical and
technical expertise.
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Changing Informed Consent for ArrayCGH
The use of ArrayCGH is an example from diagnostics where
unsolicited findings are anticipated. With this technique, chromo-
somal aberrations in the form of copy number variations can be
detected by cohybridizing sample and control DNA strands, look-
ing for gains (duplications) and losses (deletions) of nucleotides in
specific regions of the DNA [Albertson and Pinkel, 2003]. One ex-
perience of this early “genotype first” approach [Mefford, 2009] in
diagnostics has been described by Schwarzbraun et al. (2009), where
ArrayCGH was used to diagnose a 7-year-old boy with severe vi-
sual impairment, muscle hypotonia, psychomotor retardation, and
seizures. The analysis showed the boy had a deletion of the p53 gene,
increasing the risk for a Li-Fraumeni syndrome, resulting in a 50%
cancer risk in the first three decades of life [Schneider and Garber,
1993]. Netzer et al. (2009) reported a similar case with using Array-
CGH, after which they changed their informed consent procedure
to expressly decide whether: (1) patients wish to be informed about
any additional genetic finding with predictive value for the health of
the proband and potentially his/her family; (2) they only wish to be
informed about such additional genetic findings if effective treat-
ment options or surveillance programs are available; or (3) they
wish to be informed about carrier status for an autosomal recessive
disease [Netzer et al., 2009].
Others have also categorized findings to enable patients to make
a well-informed decision about having the test or not, without op-
tions for different feedback policies (e.g., see example of prenatal
ArrayCGH at the VU University Medical Center, Supp. Fig. S3).
Because of complex normative issues (including in some cases deci-
sions about termination of pregnancy) with prenatal testing, it was
perceived even more relevant to prepare parents for the possible
outcomes by presenting different categories of potential findings in
the pretest counseling.
Consent for Unsolicited Findings from NGS in Diagnostics
NGS is increasingly being used in the clinical setting. An example
of an informed consent form for exome sequencing in diagnostics
at the Radboud University Nijmegen Medical Centre (Nijmegen,
The Netherlands) can be found in Supp. Figure S4. Here, the patient
(or his/her representative) consents to the targeted as well as the
possibility of subsequently less targeted analysis of the sequence.
In this example, it was decided that an Advisory Board (in the
form described as an independent committee), consisting of a group
of independent experts from different relevant disciplines, should
decide whether an unsolicited finding should be reported to the
referring medical doctor. The patient (or his/her representative)
therefore does not agree to specified categories of information to
be fed back, and there is no opt out possibility for feedback of
unsolicited findings: if a patient does not want to be informed
about relevant unsolicited findings, he/she is not eligible for the
test.
This solution was developed because with the current experience
it was perceived difficult to predict how many and which unsolicited
findings could be expected, making it impossible to inform the
patient about this. Furthermore, the possible conflict between a
patient’s opt out for unsolicited findings and the physicians’ duty to
inform was considered to be difficult to explain to patients. Together,
this justified the, possibly temporary, solution of not offering an opt
out option for unsolicited findings. In the mean time, experience is
built on the risk of unsolicited findings [de Ligt et al., 2012] and the
experiences of patients and physicians.
In summary, the examples described here show that each con-
text led to a different focus for the discussion on the procedure
for informed consent, which to a large extent is dependent on the
decisions regarding the feedback policy. The arguments used in the
decision processes can be used as input for developing an optimal
procedure for the informed consent for NGS in diagnostics.
Practical Needs and Considerations
From the expert meeting, it also became clear that there are
several practical difficulties to overcome for the informed consent
procedure for NGS in clinical diagnostics. The most prominent
questions and needs are described below.
Handling Results After Analysis
When discussing feedback of test results, it is not always clear
what the term “result” entails. Is this the raw data, all variants
discovered, or only the interpretable and communicated results?
The default might be to refrain from disclosing raw sequence data,
which have been gained in a clinical setting, based on the fact that
it lacks obvious clinical utility. A pragmatic approach might be to
only include data that were communicated to the patient in his/her
records, but jurisdictions differ in the legal rights given to patients
to obtain access to these records. There is also ongoing discussion
on future use of the sequence and the original sample and because
this poses other complex issues, for example, related to privacy and
confidentiality [McGuire et al., 2008], a clear protocol for storage
and secondary use should be in place, of which the patient should
be informed and for which consent should be given [Porteri and
Borry, 2008].
Blurring of Boundaries Between Research and
Diagnostics: Managing Expectations
If the same professionals are involved in both clinical care and
research and as similar methods and techniques are used, it is not
always easy to make the distinction between clinical diagnosis and
research. In the case of NGS, the need to look beyond known causes
of a disease implicates a method that resembles research practice
more than the current diagnostic procedures. Because expectations
of patients could differ between different contexts, it is important
that the primary aim of the test is communicated. A way of dis-
tinguishing between clinical diagnosis and research might be to
question whether the primary goal of testing is for individual pa-
tient benefit or rather for some wider generalizable purpose, instead
of simply considering the source of the funding for sequencing. In
general, it should also be clear from the Research Ethics Committee
application and decision how the sample may be used for future
research and what information should be provided to the patient.
This is important also for primarily clinical samples as we can ex-
pect that the rapid technical development will increase the interest
in continuing the clinical investigation in a research setting [van El
et al., 2013].
Cooperation and Communication Between the Different
Parties Involved in NGS
To inform patients about what they are consenting to and to
cater to the needs of different patients in various contexts, close
cooperation between the different parties is required. Figure 1
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Figure 1. Cooperation and communication between different parties involved in the informed consent procedure for NGS in diagnostics.
depicts a model of the steps that should preferably be undertaken in
the process of informed consent for unsolicited findings for NGS,
assuming that consent is given ultimately to the full analyzing pro-
cess (targeted and if needed broader). Ideally, the informed con-
sent process in this case entails two “cycles of communication” (see
Fig. 1). In the first cycle (or the preinformed consent cycle), the pa-
tient communicates the clinical enquiry together with relevant phe-
notypic characteristics and family history to the physician, whereas
the physician assesses the patients’ needs and his/her genetic liter-
acy (step 1). Preferably, the physician communicates the relevant
information to the laboratory (step 2) to decide on the analytic
strategy and the consequential risk of unsolicited findings. This in-
formation is passed to the patient by the clinician, tailored to the
needs of the patient (step 3 and 4). In the second cycle, the patient
gives informed consent to the scope of the results that are likely
to be generated and a general strategy for feedback of results (step
5), which is communicated to the lab (step 6). The analysis and
feedback of results (step 7 and 8) is executed accordingly, taking
into account the needs of the patients as well as the interpreta-
tion of the outcome, both depending on the context (e.g., age of
patient, reproductive future, family history, etc.) [Kaphingst et al.,
2012].
It should be noted that this process depicts the ideal situation,
optimizing information exchange between the different parties at
the most appropriate time in the process. In practice, some of the
steps in the cycles could be undertaken simultaneously (e.g., step 2
and 3) and might increasingly be automated, to speed up the process
[Wright et al., 2011]. Similarly, a primary consent to targeted analysis
(similar to other genetic tests) and a separate consent after ineffective
targeted analysis are conceivable.
A Changing Role for the Lab
With the introduction of NGS in diagnostics, the role of the
laboratory geneticist changes. Detailed information on the pheno-
type and other patient characteristics are now essential to decide on
the procedure to follow for analyzing the genotype [Gilissen et al.,
2012; Hennekam and Biesecker, 2012]. This requires that the clin-
ical geneticist and the laboratory geneticist become more attuned
early in the diagnostic process, as depicted in Figure 1, which has
implications for communication, training, and education of both
specialists.
When a targeted approach is expected to be successful, this might
yield fewer unsolicited findings, thus the counseling of the clinical
geneticist should include information from the laboratory about
the amount and type of expected unsolicited findings. Although the
developing consensus in Europe is, where possible, to avoid find-
ing unsolicited disease-related variants [van El et al., 2013], some
others argue that particular known disease causing variants should
be actively sought for and followed up when performing NGS in
diagnostics [Green et al., 2013]. Besides the practical difficulties,
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this could amount to screening for conditions that would not
pass current requirements for the initiation of screening programs
[Andermann et al., 2008]. Moreover, it is questionable whether it
does justice to the patients’ right not to know when patients are
denied of the test if they decline to receive these variants.
The need to respect the patients’ right not to know also has
implications for the analytic strategies. In general, it is argued that
generating findings that are known to be clinically actionable and
not related to the clinical enquiry should be avoided as much as
possible [van El et al., 2013]. However, it might not always be feasible
to specifically block such variants when analyzing the sequence,
because it could include variants relevant for the diagnostic enquiry,
and furthermore, it will be challenging to keep an updated list of all
known disease-related variants.
Which Unsolicited Findings Should be Communicated?
To aid communication and explanation about types of unsolicited
findings and to facilitate patient decision making in the context of in-
formed consent, several attempts have been made to categorize pos-
sible unsolicited findings, sometimes referred to as “binning” [Berg
et al., 2011; Bredenoord et al., 2011; Vermeesch et al., 2012]. Cate-
gories can be defined by the nature of the condition, differentiating
between early and late-onset diseases, the level of risk/predictivity,
burden of the disease/severity, and options for treatment or
prevention.
Given the physicians duty of care and taking account of what has
been said about the patient’s right not to know (see above), the de-
fault position should be that unsolicited findings revealing diseases
or disease risks that require immediate medical treatment or pre-
vention must be disclosed [Berg et al., 2011; Committee of Ministers
and the Parliamentary Assembly of the Council of Europe, 2008].
This category should in any case be clearly defined and communi-
cated prior to testing. Opting out or consenting to feedback of other
categories was suggested by different professionals attending the ex-
pert meeting in March 2012, Amsterdam. An attempt to categorize
different types of results from NGS in diagnostics according to their
perceived need to feedback is depicted in Supp. Table S2. For some
findings, it is very clear, and consensus was easily reached on, for
example, never to disclose variants of unknown significance. Other
findings (e.g., untreatable late-onset disorders) however raised more
discussion and no final consensus was reached on the different cat-
egories, as was also experienced by others [Lohn et al., 2013]. The
complexity of defining the results that should (or should not be)
communicated lies mainly in the fact that this is dependent on the
context (e.g., whether reproductive decision making is still relevant
and if there is a family history of genetic disorders). Furthermore,
the categories might differ between adults and children, because dif-
ferent ethical challenges might be raised for children [Bredenoord
et al., 2013; Dondorp et al., 2012; Lantos et al., 2011].
Limits to Informing and Decision Making
In general, it is very difficult (if not impossible) to inform pa-
tients about all possible kinds of outcomes. Certain groups of pa-
tients (e.g., less well-educated people and people from minority
racial/ethnic groups) may have even more difficulty with processing
the information from the informed consent procedure for genome
sequencing and therefore require special attention [Kaphingst et al.,
2012]. Currently, most patients considered for exome sequencing
are children or cognitively impaired people. In these cases, proxy
consent is usually taken, as the patient lacks the capacity to consent
for himself/herself. Despite the inherent difficulties with provid-
ing sufficient information and with facilitating the decision-making
process, our view is that in principle patients should have the right
to opt out from feedback of unsolicited findings, because they fall
outside the primary aim of the test.
It is anticipated that in the future it will not only be clinical geneti-
cists, but also other specialists that will be involved in the informed
consent process for NGS. The participants of the 2012 expert meet-
ing concluded that in the short term, and until clear guidelines have
been developed, it is preferred that a clinical geneticist is involved at
least when disclosing results, because of his/her expertise in dealing
with complex and sensitive genetic issues. In the medium term, it
seems likely that clear guidelines will be developed based on current
experiences that might facilitate the involvement of other appropri-
ately qualified health professionals in communicating NGS findings
to patients. For example, more debate is required to reach consensus
on the exact elements of information required for informed consent
[Ayuso et al., 2013].
Involvement of an Advisory Board for Unsolicited Findings
In the transitional phase, while gaining more experience with un-
solicited findings with diagnostic NGS, it may be helpful to involve
an independent Advisory Board in the decision on follow-up of
unsolicited findings, in particular when it is considered difficult to
decide what to disclose. For this procedure, according to the partic-
ipants at the 2012 expert meeting, the following points should be
considered:
(1) The results should be confirmed (with traditional methods, for
example, Sanger sequencing) before they are communicated to
the Advisory Board.
(2) The Advisory Board should consist of individuals from dif-
ferent disciplines, preferably including a laboratory geneticist,
a clinical geneticist (if possible independent of the case dis-
cussed), an ethicist, a legal expert (trained/experienced in the
subject of NGS and unsolicited findings), and preferably a lay
member/social worker (to represent the patients perspective).
(3) It should be clear that the Advisory Board only has an advisory
role: the clinical geneticist treating the patient is responsible for
the final actions undertaken.
(4) It is preferred that the treating clinical geneticist is informed
about the result only after the Advisory Board has given its
advice to disclose the findings, to protect the clinician from an
internal conflict between the patient’s right not to know and
the duty to inform.
(5) While in the beginning more cases will be discussed by the
committee, it might be most practical that (local) standards
are developed as soon as possible for more common outcomes,
and the Advisory Board will only be consulted for more difficult
cases.
Conclusions
The development of NGS technologies, and their use in clinical
settings for diagnosis, arguably offers new challenges to the feasibil-
ity of the requirement for informed consent as traditionally under-
stood. One of the main conflicts in NGS for diagnostics is encoun-
tered between the “right to know” and the “right not to know” of the
patient and his/her family on the one hand and the duty of care of the
clinician on the other. This becomes complex especially when proxy
consent is given by a parent or caretaker of a minor. Traditionally, in
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clinical practice, the patient’s autonomy is valued highly, but in the
case of NGS, it is unclear whether it is feasible to help the patient
make a fully informed decision. Although models for categorizing
different types of results (“binning”) have been developed, there are
some challenges to implementing these approaches. For example, it
seems currently impossible for the lab to confirm every result when
a patient decides he/she would like to be informed about all find-
ings. Furthermore, even with a binning system, it remains difficult
for clinicians to explain the complexity of all possible outcomes.
Due to this complexity, even when comprehending all information
provided, it might be very difficult for individuals to foresee the
implications and decide on the various different feedback proce-
dures beforehand. Although it may seem paternalistic and unlike
the established procedures in clinical genetics, it can be argued that
the final decision of what to feedback to the patient should be in
the hands of the physician. The reason to choose this position is
first, that prior to testing only general information can be discussed,
whereas after the test results are available, professionals will have to
decide about disclosure on the basis of specific outcomes; and sec-
ond, that the possible health interests of the patient’s relatives may be
at stake.
To ensure an optimal effort to provide good practice in the in-
formed consent procedure for NGS in diagnostics, cooperation and
communication between different parties are needed in multiple
steps in the process (see Fig. 1). Furthermore, we propose a set of
questions to consider for systematically gaining insight in the de-
gree of feedback the patient should and could be able to decide
upon when reporting back results from NGS in diagnostics (see
Box 1).
Box 1. Points to Consider when Contemplating the Mode
of Informed Consent for NGS in Diagnostics
(1) Who is giving consent: the patient or his/her legal repre-
sentative? (i.e., how strong is the “right not to know”)
(2) What is the initial clinical enquiry?
(3) Which unsolicited findings can be expected?
(4) How can the different possible unsolicited findings be cat-
egorized? (Supp. Table S1)
(5) What should be communicated to the patient?
(a) Which pretest information? (Fig. 1: cycle of commu-
nication 1)
(b) Which results? (Fig. 1: cycle of communication 2)
(6) What does this mean for the consent procedure?
(a) General/detailed?
(b) Oral/written consent?
(c) Advisory Board involved?
(d) Opt in or opt out of unsolicited findings?
By addressing each question, different facets of the informed
consent procedure receive attention, ensuring an optimal effort to
provide good practice in the clinical genetic service of using NGS in
diagnostics.
With regard to best practice for informed consent for NGS, we are
aware that this article cannot provide definitive policy recommen-
dations, as this field is evolving rapidly, but hope that the systematic
process set out in this article provides a sound basis for developing
the informed consent procedure for NGS in diagnostics.
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